UCB dips despite posting strong first six months financials

28 July 2022
ucb_sign_large

Belgium’s largest pharma company UCB (Euronext: UCB) this morning posted financial results for the first half of 2022, which it described as “strong,” but investors were not convinced, sending the firm’s shares more than 4% lower to 77.92 euros.

Revenue increased to 2.93 billion euros ($2.97), +5%; +3% constant exchange rates (CER), net sales were 2.70 billion (+2%; 0% CER) – impacted by generic erosion on two leading brands.

Underlying profitability (adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was 814 million euros (-3%; -2% CER), 28% of revenue – impacted by the inclusion since March of Zogenix, which UCB acquired for $1.9 billion. Core earnings per share were down 7% at 3.15 euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical